BTK inhibitor therapy has also been tested in DLBCL patients in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) therapy in several clinical trials with varying success [3, 4, 5, 6]. Here, BTK is linked to diffuse large B-cell lymphoma.